Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00070499 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 410 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv410
  2. Study sites revised (340)v409 See this version in full on ClinicalTrials.gov ↗
  3. Study sites revised (340)v408 See this version in full on ClinicalTrials.gov ↗
  4. Study sites revised (340)v407 See this version in full on ClinicalTrials.gov ↗
  5. Study sites: 341 to 340v406
  6. Completion pushed from Mar 10, 2026 to Mar 10, 2027 Study sites revised (341)v405 Show 1 more changeShow less
    • Study sites revised (341)

    See this version in full on ClinicalTrials.gov ↗

  7. 8 versions Re-verified since Mar 11, 2026, no change to tracked fieldsv397-v404
  8. Study sites revised (341)v396 See this version in full on ClinicalTrials.gov ↗
  9. 4 versions Re-verified since Mar 4, 2026, no change to tracked fieldsv392-v395
  10. Study sites revised (341)v391 See this version in full on ClinicalTrials.gov ↗
  11. Re-verified, no change to tracked fieldsv390
  12. Study sites revised (341)v389 See this version in full on ClinicalTrials.gov ↗
  13. Study sites revised (341)v388 See this version in full on ClinicalTrials.gov ↗
  14. Study sites revised (341)v387 See this version in full on ClinicalTrials.gov ↗
  15. Study sites revised (341)v386 See this version in full on ClinicalTrials.gov ↗
  16. Completion date: Feb 22, 2025 to Mar 10, 2026 Study sites revised (341)v385 Show 1 more changeShow less
    • Study sites revised (341)

    See this version in full on ClinicalTrials.gov ↗

  17. Re-verified, no change to tracked fieldsv384
  18. Study sites revised (341)v383 See this version in full on ClinicalTrials.gov ↗
  19. Study sites revised (341)v382 See this version in full on ClinicalTrials.gov ↗
  20. Study sites revised (341)v381 See this version in full on ClinicalTrials.gov ↗
  21. Study sites revised (341)v380 See this version in full on ClinicalTrials.gov ↗
  22. Study sites revised (341)v379 See this version in full on ClinicalTrials.gov ↗
  23. Study sites revised (341)v378 See this version in full on ClinicalTrials.gov ↗
  24. Re-verified, no change to tracked fieldsv377
  25. Study sites revised (341)v376 See this version in full on ClinicalTrials.gov ↗
  26. Study sites revised (341)v375 See this version in full on ClinicalTrials.gov ↗
  27. Study sites revised (341)v374 See this version in full on ClinicalTrials.gov ↗
  28. Study sites revised (341)v373 See this version in full on ClinicalTrials.gov ↗
  29. Study sites revised (341)v372 See this version in full on ClinicalTrials.gov ↗
  30. Completion date: Feb 22, 2025v371
  31. Re-verified, no change to tracked fieldsv370
  32. Study sites revised (341)v369 See this version in full on ClinicalTrials.gov ↗
  33. Study sites revised (341)v368 See this version in full on ClinicalTrials.gov ↗
  34. Re-verified, no change to tracked fieldsv367
  35. Study sites revised (341)v366 See this version in full on ClinicalTrials.gov ↗
  36. Re-verified, no change to tracked fieldsv365
  37. Site details revised at 1 of 341 sitesv364
  38. Study sites revised (341)v363 See this version in full on ClinicalTrials.gov ↗
  39. Re-verified, no change to tracked fieldsv362
  40. Study sites revised (341)v361 See this version in full on ClinicalTrials.gov ↗
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This randomized phase IIB trial studies imatinib mesylate at two different doses and dasatinib to see how well they work in treating patients with previously untreated chronic phase chronic myelogenous leukemia. Imatinib mesylate or dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Trial Details
NCT Number NCT00070499
Lead Sponsor National Cancer Institute (NCI)
Conditions Chronic Myeloid Leukemia, BCR-ABL1 Positive
Enrollment 406 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov